Pablo Corral/LinkedIn
Nov 9, 2025, 01:51
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”AHA 2025 | CORALreef Lipids Trial
A true game changer in lipid management.
Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).
- Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
- Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
- A new era in PCSK9 inhibition and cardiovascular prevention.”
Stay updated with Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke